Estimation of induction and maintenance costs of infliximab, adalimumab and certolizumab pegol in managing Crohn's disease

被引：0
|
作者：
Feagan, Brian
Tan, Seng
Malone, Daniel
Hinojosa, Joaquin
Brown, Martin
机构：
[1] Robarts Res Inst, London, ON N6A 5C1, Canada
[2] UCB, Global Hlth Outcomes Res, Slough, Berks, England
[3] Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA
[4] Hosp Sagunto, Gastroenterol Unit, Valencia, Spain
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2008年 / 103卷
关键词：
D O I：
10.14309/00000434-200809001-00999
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
999
引用
收藏
页码：S392 / S392
页数：1
相关论文
共 50 条
  • [21] Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to Infliximab
    Sandborn, William J.
    Abreu, Maria T.
    D'Haens, Geert
    Colombel, Jean-Frederic
    Vermeire, Severine
    Mitchev, Krassimir
    Jamoul, Corinne
    Fedorak, Richard N.
    Spehlmann, Martina E.
    Wolf, Douglas C.
    Lee, Scott
    Rutgeerts, Paul
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2010, 8 (08) : 688 - 695
  • [22] Assessment of the Efficacy of Certolizumab Pegol in the Maintenance of Response for the Treatment of Crohn's Disease
    Lee, Scott D.
    Ko, Cynthia W.
    Wahbeh, Ghassan
    Cullinan, Cory
    Etter, Scott
    Sinanan, Mika N.
    Wheat, Chelle
    GASTROENTEROLOGY, 2011, 140 (05) : S282 - S282
  • [23] Certolizumab pegol in Crohn's disease - A viewpoint
    Abreu, Maria T.
    BIODRUGS, 2007, 21 (03) : 202 - 203
  • [24] Efficacy of Certolizumab Pegol Induction and Maintenance Therapy in Patients With Crohn's Disease Not in Remission Following Active or Placebo Induction
    Sandborn, William J.
    Younes, Ziad H.
    Pierre-Louis, Bosny
    D'Haens, Geert R.
    GASTROENTEROLOGY, 2012, 142 (05) : S565 - S565
  • [25] Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease
    Hanauer, S. B.
    Panes, J.
    Colombel, J. -F.
    Bloomfield, R.
    Schreiber, S.
    Sandborn, W. J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 32 (03) : 384 - 393
  • [26] Certolizumab pegol for the treatment of Crohn's disease
    Sandborn, William J.
    Feagan, Brian G.
    Stoinov, Simeon
    Honiball, Pieter J.
    Rutgeerts, Paul
    Mason, David
    Bloomfield, Ralph
    Schreiber, Stefan
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (03): : 228 - 238
  • [27] Certolizumab pegol in the treatment of Crohn's disease
    Ferrante, Marc
    Vermeire, Severine
    Rutgeerts, Paul
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (04) : 595 - 605
  • [28] Certolizumab pegol for the treatment of Crohn's disease
    Baker, Danial E.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2009, 5 (06) : 683 - 691
  • [29] A retrospective comparison of infliximab versus adalimumab as induction and maintenance therapy for Crohn disease
    Varma, P.
    Paul, E.
    Huang, C.
    Headon, B.
    Sparrow, M. P.
    INTERNAL MEDICINE JOURNAL, 2016, 46 (07) : 798 - 804
  • [30] Antibodies to infliximab in patients with Crohn's disease do not cross-react with certolizumab pegol
    Vetterlein, O.
    Kopotsha, T. M.
    Nesbitt, A. M.
    Brown, D. T.
    Stephens, S.
    GUT, 2007, 56 : A116 - A116
12345